Program
acalabrutinib
Also written as “Acalabrutinib”, “ACP-196” and “Acalabrutinib (ACP-196)”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Mantle-Cell · Lymphoma, Large B-Cell, Diffuse · COVID-19 · Hepatic Insufficiency, led by 4 companies.
Drug pageAcalabrutinib: every studyAll 123 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 5220 open or running | phase 4since Jun 11, 2021 | Jan 6, 2014 | Feb 15, 2027phase 3 · NCT02972840 |
| AbbVieits history only | 11 open or running | phase 3since May 20, 2024 | May 20, 2024 | Mar 2028phase 3 · NCT06428019 |
| Ascentage Pharma Group Internationalits history only | 11 open or running | phase 3since Mar 13, 2024 | Mar 13, 2024 | Aug 2027phase 3 · NCT06319456 |
| Ipsen | 10 open or running | phase 2since Dec 29, 2021 | Dec 29, 2021 | none ahead |
Also a collaborator on its studies: Apices Soluciones S.L., Hoffmann-La Roche, Fortrea, eResearch Technology, CISCRP, Parexel, Merck and Eli Lilly.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Ipsen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2015Named acalabrutinibINNProposed as its International Nonproprietary Name in WHO's List 113 · before, ACP-196
- Dec 29, 2021First study: phase 2 study in Hematologic NeoplasmsFirst studyNCT05205252 · United States
TargetBeta
“An orally available inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor; Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| tirabrutinibrule | Gilead Sciences | phase 3 | 13 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
The one study Ipsen leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05205252Hematologic Neoplasms · United States | 2 | Withdrawn | Jul 5, 2023 | 0 |
How it is read
Names in the registry
- “Acalabrutinib”, 28 entries
- “acalabrutinib”, 7 entries
- “ACP-196”, 7 entries
- “Acalabrutinib (ACP-196)”, 3 entries
- “ACP-196 (acalabrutinib)”, 2 entries
Codes read as this program: ACP196.
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 14 studies
- Lymphoma, Mantle-Cell, 8 studies
- Lymphoma, Large B-Cell, Diffuse, 3 studies
- COVID-19, 3 studies
- Hepatic Insufficiency, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.